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Dissolution enhancementAbstract A solid self-nanoemulsifying drug-delivery system (solid SNEDDS) has been explored to
improve the solubility and dissolution proﬁle of glipizide. SNEDDS preconcentrate was system-
atically optimized using a circumscribed central composite design by varying Captex 355 (Oil),
Solutol HS15 (Surfactant) and Imwitor 988 (Co-surfactant). The optimized SNEDDS preconcen-
trate consisted of Captex 355 (30% w/w), Solutol HS15 (45% w/w) and Imwitor 988 (25% w/w).
The saturation solubility (SS) of glipizide in optimized SNEDDS preconcentrate was found to
be 45.12 ± 1.36 mg/ml, indicating an improvement (1367 times) of glipizide solubility as compared
to its aqueous solubility (0.033 ± 0.0021 mg/ml). At 90% SS, glipizide was loaded to the optimized
SNEDDS. In-vitro dilution of liquid SNEDDS resulted in a nanoemulsion with a mean droplet size
of 29.4 nm. TEM studies of diluted liquid SNEDDS conﬁrmed the uniform shape and size of the
globules. The liquid SNEDDS was adsorbed onto calcium carbonate and talc to form solid
SNEDDS. PXRD, DSC, and SEM results indicated that, the presence of glipizide as an amorphous
and as a molecular dispersion state within solid SNEDDS. Glipizide dissolution improvedse in 15
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(18.37%) and commercial product (65.82) respectively.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf of King SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Glipizide: 1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carbox-
amido) ethyl] benzene sulphonyl} urea is an antidiabetic. It is
given orally for the treatment of type II diabetes mellitus. Glip-
izide acts to lower blood glucose by stimulating the release of
pancreatic b cell (Sweetman, 2009). Glipizide, a weak acid
(pKa = 5.9) is practically insoluble in water (Wilson et al.,
2004). Owing to its poor solubility, several formulation
approaches have been investigated, including cyclodextrin
complex (Gan et al., 2002; Huang et al., 2013; Nie et al.,
2011; Shivakumar et al., 2007; Zhang et al., 2008), solid disper-
sion (Isaac et al., 2013), nanosuspension (Mahesh et al., 2014),
bionanocomposites (Kushare and Gattani, 2013), co-solvent
assisted solubilization (Seedher and Kanojia, 2009) and
microparticles (Madhusudhan et al., 2010) to improve solubi-
lity of glipizide.
Self-nanoemulsifying drug-delivery systems (SNEDDS)
have emerged as an effective delivery system due to their pro-
ven ability to enhance bioavailability of lipophilic drugs (Singh
et al., 2013). SNEDDS is a thermodynamically stable isotropic
mixture of oil, surfactant, co-surfactant and drug that form a
spontaneous oil-in-water nanoemulsion with a droplet size less
than 100 nm when introduced into an aqueous medium under
gentle agitation (Bali et al., 2011).
Several potential advantages of SNEDDS include their
ability to present drug in a solubilized form inside the gastroin-
testinal (GI) lumen, thus providing greater interfacial area for
drug absorption, providing greater chemical and enzymatic
stability, inhibiting P-glycoprotein (p-gp) mediated drug efﬂux,
enhancing lymphatic transport (Date et al., 2010; Seo et al.,
2013).
Components of SNEDDS and their concentrations have
profound effect upon droplet size of the formed nanoemulsion
which may affect its in-vitro and in-vivo performance (Hu et al.,
2012). However, such formulations often developed and opti-
mized using a trial-and-error approach by varying one-fac-
tor-at-a-time keeping rest factors constant. This univariate
approach is time-consuming and requires a larger number of
experiments to describe the effect of excipients (oil, surfactant
and co-surfactant) on the physical properties of the SNEDDS
and frequently fails to project the true optimal composition
because interactions between factors were not considered
(Pund et al., 2014). For understanding the multi-factorial rela-
tionship between formulation factors and product quality usu-
ally requires the use of multivariate approach, such as
statistical design of experiment (DOE) (Wu et al., 2011). Sys-
tematic optimization of pharmaceutical product using DOE
requires fewer experimental runs and tends to reveal (any) syn-
ergism or interaction among factors. Which in turn leads to
yield a robust formulation with advantages of economics in
terms of time, money and development efforts (Singh et al.,
2013).Moreover, it is worthy to convert conventional liquid
SNEDDS to a solid dosage form (solid SNEDDS) having high
stability, better transportability, simple and cost effective
manufacturing, and above all, the improved therapeutic suc-
cess owing to better patient compliance (Balakrishnan et al.,
2009; Hu et al., 2012). Thus, the present research work aim
at developing a solid SNEEDS of glipizide by systematically
optimizing the SNEDDS preconcentrate that would generate
a nanoemulsion on dilution. The generation of a nanoemulsion
could provide a large interfacial surface area for drug solubi-
lization leading to an enhanced solubility and dissolution of
glipizide.2. Materials and methods
2.1. Materials
Pharmaceutical grade of glipizide was a generous gift from
Alembic Ltd., Vadodara, India. Abitec Corp., Janesville,
USA, supplied EP/NF grade of medium chain tri-glycerides
(Captex 300, and Captex 355) and medium chain mono-g-
lycerides (Capmul MCM,). EP grades of poly-glycol mono
and di-esters of 12-hydroxy stearic acid (Solutol HS15) and
polyethylene glycol-40 hydrogenated castor oil (Cremophor
RH40); provided by BASF SE, Ludwigshafen, Germany. EP
grade of medium chain tri-glycerides (Labrafac lipophile
WL 1349, Labrafac PG) and PEG-8 glyceryl caprylate
(Labrasol) were supplied by Gattefosse Corp., Saint-Priest,
France. EP grades of medium chain tri-glycerides (Miglyol
812 N) and medium chain mono-glycerides (Imwitor 988)
were supplied by Sasol, GmbH Germany. Tween 80,
Coconut oil, Castor oil, Olive oil, and Polyethylene glycol
400 (PEG 400) were purchased from Himedia Lab. Private
Ltd., Mumbai, India. Capsugel Health Care Ltd., Mumbai,
India, supplied size ‘‘1’’ hard gelatin capsule shell. 18 MO
Water (HPLC grade) obtained in-house from a Direct Q-3
UV water puriﬁcation system (Millipore India Pvt. Ltd.,
Bengaluru, India).
2.2. Analytical methodology
A reversed phase HPLC method was developed in-house to
quantify glipizide in samples obtained from solubility and dis-
solution studies. The analysis was performed on the Perkin
Elmer HPLC system (Series 200) at a temperature of
30 ± 2 C. The column used (Luna C8, 100 · 4.6 mm, 3 lm)
was from Phenomenex, CA, USA, while the mobile phase
was acetonitrile–potassium dihydrogen orthophosphate buffer
(pH 4.5; 20 mM) (35:65, v/v). Mobile phase ﬂow rate, detec-
tion wavelength and injection volume were 0.8 ml/min,
226 nm and 20 ll respectively. The method was linear
(r2 = 0.999) in the concentration range of 0.05–70 lg/ml.
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2.3. Determination of glipizide solubility in oils, optimized
SNEDDS preconcentrate and water
Solubility of glipizide determined using the shake ﬂask
method. An excess of glipizide was added to vials containing
two ml of each medium chain triglyceride (MCT)/synthetic oils
(Captex 300, Captex 355, Labrafac lipophile WL1349, Labra-
fac PG and Miglyol 812 N); long chain triglycerides (LCT)
(Coconut oil, Olive oil and Castor oil) and optimized
SNEDDS (a mixture of oil, surfactant and co-surfactant).
The vials stirred in water bath at 37 ± 0.5 C for 7 days to
attain equilibrium. Similarly, an excess amount of glipizide
was added to 10 ml of water (HPLC) and processed as above.
All the samples were centrifuged at 5000 rpm for 15 min
(RM-12C, Remi-instruments, Mumbai, India) and analyzed
for glipizide content by HPLC.
2.4. Screening of surfactants and co-surfactant for emulsifying
ability
Surfactant and co-surfactants were selected based upon their
ability to emulsify rather than to solubilize the drug
(Basalious et al., 2010). Surfactants and Co-surfactants were
screened in accordance with the method described by Date
and Nagarsenker, 2007 with minor modiﬁcation. For surfac-
tant screening, 500 mg of each surfactant (Cremophor RH40,
Solutol HS15, Labrasol, Cremophor EL and Tween 80) was
mixed with 500 mg of oil (selected from solubility study).
The mixture was gently heated at 40 C to homogenize the
components. Each mixture (0.1 g) was reconstituted with
50 ml of water (HPLC) in a volumetric ﬂask. The resulting
emulsions were visually observed for emulsion formation by
noting the number of ﬂask inversion. Percentage transmittance
(at 638.2 nm) (Date and Nagarsenker, 2007; Gupta et al.,
2011) and turbidity were measured by UV–Vis spectropho-
tometer (T80+, PG Instrument, UK) and Digital Nephlo-tur-
bidity meter (132, Systronics, India) respectively using water
(HPLC) as blank.
For Co-surfactant screening, 100 mg of each co-surfactant
(Imwitor 988, Capmul MCM, Capmul PG8 and PEG 400)
was mixed with 200 mg of a surfactant (selected from surfac-
tant screening) at 1:2 ratios. 300 mg of oil was added to the
above mixture of surfactant and co-surfactants at 1:1 ratio.
The mixture gently heated at 40 C to homogenize the compo-
nents and diluted 500 times with water (HPLC). The formed
emulsions were accessed for different parameters as mentioned
under surfactant screening.
2.5. Ternary phase diagram
To identify the region of nanoemulsion, a ternary phase dia-
gram was plotted for the selected oil, surfactant and co-surfac-
tant, each representing an apex of a triangle. A series of
mixtures (2 g each) with varying oil, surfactant and co-surfac-
tant were prepared. The levels of oil, surfactant and co-surfac-
tant were varied from 10 to 80, 10 to 80 and 10 to 50 parts by
weight respectively. For any mixture, the sum of oil, surfactantand co-surfactant was 100%. 100 mg of each mixture was
added to 20 ml water (HPLC) and agitated gently at 50 rpm
using a magnetic stirrer (2MLH, Remi, Mumbai, India). The
generated emulsion having a clear or slightly bluish in appear-
ance was considered as the nanoemulsion (Basalious et al.,
2010).
2.6. Optimization of SNEDDS preconcentrate using
experimental design
A central composite design (CCD) was employed for the
optimization of SNEDDS by varying its components/factor
such as Captex 355 (X1), Solutol HS15 (X2), and Imwitor
988 (X3). The factors were varied between 20–60 parts by
weight of X1, 20–60 parts by weight of X2 and 10–30 parts
by weight of X3. The experimental plan was designed using
Minitab version 16 (Minitab, Inc. UK). Twenty formula-
tions (2 g each) with six central points (run order 3, 5, 11,
14, 15 and 17) were prepared by mixing various portions
of oil, surfactant and co-surfactant as recommended by the
experimental plan (Table 1). Each formulation was diluted
with HPLC water (500 times) and assessed for responses such
as mean droplet size (nm) (Y1), turbidity (NTU) (Y2), and
percentage transmittance (Y3) (Nazzal and Khan, 2002;
Pund et al., 2014; Rahman et al., 2012). The optimization’s
goal was kept to minimize Y1 (<50 nm), Y2 (<20 NTU)
and to maximize Y3 (>99%) The parts by weight of X1,
X2 and X3 were converted to the percentage by weights
before analyzing the result using Statistica version 10.0 (Stat
soft, Inc. USA) and Design Expert version 8.0 (Stat-Ease,
Minneapolis, USA). A best ﬁtted quadratic equation was
built for each response Eq. (1).
Y ¼ b0þ b1ðX1Þ þ b2ðX2Þ þ b3ðX3Þ þ b11ðX1Þ2
þ b22ðX2Þ2 þ b33ðX3Þ2 þ b12ðX1X2Þ þ b13ðX1X3Þ
þ b23ðX2X3Þ ð1Þ
where Y, the response; b0, arithmetic means for a particular
response; b1, b2 and b3 are the regression coefﬁcient for factor
X1, X2 and X3 respectively. A positive coefﬁcient indicates
a synergistic effect, while a negative one represents an
antagonistic effect. ANOVA was employed to validate these
models. Model adequacy tested by inspection of residual plots.
The optimum SNEDDS preconcentrate composition was
determined using Derringer’s desirability function.
2.7. Preparation of liquid SNEDDS
The liquid SNEDDS prepared by dissolving glipizide at 90%
SS in optimized SNEDDS preconcentrate. Brieﬂy, 400 mg
of glipizide was added to 10 g of SNEDDS preconcentrate
and mixed for ﬁve minutes with a Cyclo-mixer (CM101,
Remi-instruments, Mumbai, India) to get a clear solution.
2.8. Characterization of liquid SNEDDS
2.8.1. Thermodynamic stability studies
Liquid SNEDDS was subjected to thermodynamic stability
studies in order to access any phase separation and stability
Table 1 Details of experiments performed along with outcomes during optimization of SNEDDS preconcentrate by a central
composite design.
Std. order Run order X1 X2 X3 X1 X2 X3 Y1 Y2 Y3
By parts (w/w) By percentage (w/w) Obs.a Pred.b Obs.a Pred. b Obs.a Pred.b
8 1 60.00 60.00 30.00 40.00 40.00 20.00 47.8 30.5 24.3 4.8 99.3 100.8
7 2 20.00 60.00 30.00 18.18 54.54 27.27 42.9 61.3 10.5 22.0 99 95.5
18 3 40.00 40.00 20.00 40.00 40.00 20.00 45.4 48.0 12.2 22.7 99 98.5
10 4 73.63 40.00 20.00 55.10 29.93 14.96 121.1 123.3 175.8 172.8 81 81.3
16 5 40.00 40.00 20.00 40.00 40.00 20.00 49.1 48.0 27.6 22.7 98.2 98.5
4 6 60.00 60.00 10.00 46.15 46.15 7.69 76.6 90.9 112.8 136.3 96.2 93.9
14 7 40.00 40.00 36.81 34.24 34.24 31.51 58.6 55.9 45.8 57.1 97.8 99.5
11 8 40.00 6.364 20.00 60.27 9.58 30.13 158.4 156.9 190.5 186.4 78 78.6
3 9 20.00 60.00 10.00 22.22 66.66 11.11 35.6 18.3 7.5 1.1 99.3 101.4
6 10 60.00 20.00 30.00 54.54 18.18 27.27 105.2 122.7 162.0 173.3 84.8 81.6
17 11 40.00 40.00 20.00 40.00 40.00 20.00 46.5 48.0 19.2 22.7 98.3 98.5
1 12 20.00 20.00 10.00 40.00 40.00 20.00 47.1 64.5 22.5 46.9 98 95.4
12 13 40.00 73.63 20.00 29.93 55.10 14.96 39.5 40.5 9.4 6.2 99 99.7
15 14 40.00 40.00 20.00 40.00 40.00 20.00 49.7 48.0 29.5 22.7 98.7 98.5
20 15 40.00 40.00 20.00 40.00 40.00 20.00 45.8 48.0 14.2 22.7 98.9 98.5
5 16 20.00 20.00 30.00 28.57 28.57 42.85 84.7 70.5 121.8 103.3 95.9 97.1
19 17 40.00 40.00 20.00 40.00 40.00 20.00 51.9 48.0 32.8 22.7 98.7 98.5
9 18 6.36 40.00 20.00 9.58 60.27 30.13 20.9 18.3 4.6 0.3 99.9 100.5
13 19 40.00 40.00 3.18 48.08 48.08 3.82 99.4 101.6 138.7 120.2 92.8 92.4
2 20 60.00 20.00 10.00 66.66 22.22 11.11 238.4 220.1 275.8 269.2 64.8 67.2
X1, Captex 355; X2, Solutol HS 15; X3, Imwitor 988; Y1, mean droplet size (nm); Y2, turbidity (NTU) and Y3, percentage transmittance.
a Observed.
b Predicted.
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Shakeel et al., 2013).
2.8.1.1. Centrifugation test. Liquid SNEDDS was diluted 500
times with water (HPLC). Two ml of the diluted portion cen-
trifuged at 5000 rpm (RM 12C, Remi, Mumbai, India) for
30 min and was observed visually for any sign of phase
separation.
2.8.1.2. Heating and cooling cycle. Liquid SNEDDS was sub-
jected to six cycles of heating (40 C) and cooling (4 C) with
48 h storage at each temperature. Afterward, it was assessed
for phase separation.
2.8.2. Cloud point measurement
Liquid SNEDDS was diluted 500 times with water (HPLC)
and placed into a water bath, and the temperature increased
gradually. The temperature at which a sudden appearance of
turbidity occurs was recorded. This was veriﬁed by measuring
turbidity using a Nephlo-turbidity meter (132, Systronics,
India) (Bandyopadhyay et al., 2012).
2.8.3. Measurement of droplet size analysis and zeta potential
0.1 g of liquid SNEDDS was diluted with 50 ml of water
(HPLC) in a volumetric ﬂask. The ﬂask was inverted and shak-
en gently to form a ﬁne emulsion and allowed to stand for 12 h
at room temperature (Balakrishnan et al., 2009). The droplet
size and zeta potential of the diluted liquid SNEDDS was
determined using dynamic light scattering (DLS) techniques
with a particle sizer (Nanopartica SZ100, Horiba instrument,
UK).2.8.4. Measurement of transmittance and turbidity
The percentage transmittance and turbidity of the formed
emulsion in Section 2.8.3 were measured using UV–Vis spec-
trophotometer (T80+, PG Instrument, UK) and Digital
Nephlo-turbidity meter (132, Systronics, India) respectively
using water (HPLC) as blank.
2.8.5. Transmission electron microscopy
The morphology of the formed nanoemulsion in Section 2.8.3
was determined using transmission electron microscopy
(TEM) (JEM-1200EX, Jeol, Japan). A drop of diluted liquid
SNEDDS spread on a 200-mesh, copper grid and positively
stained with 0.5% uranyl acetate for 30 s. The grid dried at
room temperature and then observed using TEM.
2.9. Preparation of solid SNEDDS and determining drug
content
Liquid SNEDDS was adsorbed onto a popular inorganic
adsorbent such as Calcium carbonate (Tang et al., 2008).
Brieﬂy, 10 g of liquid SNEDDS (obtained in Section 2.7)
was poured onto calcium carbonate (15 g) placed in a mortar,
mixed for ﬁve minutes to obtain a homogenous mass. 2 g of
Talc (used as lubricant) was added to the above mass, mixed
gently, and passed through a 250 lm mesh. Similarly, a solid
SNEDDS blank prepared using above excipients in the same
proportion but without using glipizide.
For determining drug content, the 100 mg of solid
SNEDDS was transferred into 10 ml volumetric ﬂask, and
the volume made up to mark with methanol (HPLC) and
sonicated for 10 min. Two ml of the above solution was diluted
532 R.N. Dash et al.to 10 ml with mobile phase, mixed, ﬁltered through a 0.22 lm
nylon ﬁlter, and injected six times into the HPLC system.
Similarly, blank injections were made in the same way by using
solid SNEDDS blanks. The amount of solid SNEDDS equiva-
lent to 5 mg of glipizide was ﬁlled into size ‘‘1’’ hard gelatin
capsules (Capsugel, Mumbai, India) and stored at 25 C until
used for the subsequent studies.
2.10. Characterization of solid SNEDDS
2.10.1. Droplet size of reconstituted solid SNEDDS
Content of one capsule of Solid SNEDDS was reconstituted in
50 ml of water (HPLC), allowed to stand for 12 h at room tem-
perature and the droplet size was of formed emulsion was mea-
sured as per the procedure stated under liquid SNEDDS
(Section 2.8.3).
2.10.2. Micromeritic properties
Important micromeritic properties such as Carr’s index,
Hausner’s ratio, and angle of repose of solid SNEDDS were
determined using the standard procedure (Carr, 1965).
2.10.3. Scanning electron microscopy (SEM)
The outer macroscopic structures of glipizide, solid SNEDDS,
solid SNEDDS blank, and physical mixtures (1:1 mixture
of glipizide and solid SNEDDS blank) were investigated by
S-4100 scanning electron microscope (Hitachi, Japan) at an
accelerating voltage of 15 keV.
2.10.4. Powder XRD studies
X-ray powder scattering measurements on the samples (men-
tioned in Section 2.10.3) and individual excipients of solid
SNEDDS (e.g. Calcium carbonate and Talc) were carried
out with an X-ray diffractometer (D8 Advanced, Bruker
AXS, Germany). The instrument uses Cu Ka radiation gener-
ated at 40 kV voltage and 40 mA current. The 2h angle
increased at a step of 0.1 within 6–50.
2.10.5. Differential scanning calorimetry (DSC)
DSC analysis of the samples mentioned in Section 2.10.4 was
carried out using Pyris 6 DSC thermal analyzers (Perkin
Elmer, USA). Samples were scanned at a temperature incre-
ment of 10 C/min from 40 to 320 C.
2.10.6. In-vitro dissolution studies
In-vitro dissolution studies were conducted for the solid
SNEDDS, liquid SNEDDS, marketed product (Glucotrol,
Pﬁzer Inc. USA) and pure drug each containing 5 mg of
glipizide. Studies conducted using a USP dissolution type-I
apparatus (TDT-08L, Electrolab, Mumbai, India) with
900 ml of pH 6.8 phosphate buffer as the dissolution medi-
um maintained at 37 ± 0.5 C. The basket speed was adjust-
ed to 75 rpm. At a predetermined time interval, an aliquot
(ﬁve ml) of the samples were collected and replaced with
fresh dissolution medium. The collected samples were suit-
ably diluted with mobile phase, ﬁltered through 0.22 lm
membrane ﬁlter and analyzed for the glipizide content by
HPLC.3. Results and discussion
3.1. Solubility study of glipizide and selection of oil
The oil, which is an important excipients in the self-emulsifying
formulation enhances solubility and fraction of lipophilic
drugs transported through the intestinal lymphatic system,
thus increasing absorption through the GI tract (Gursoy and
Benita, 2004). The drug loading capability is the main factor
needs to be considered during the screening of the oily phase
for a self-emulsifying formulation (Pouton, 2000). The satura-
tion solubility of glipizide in LCT such as Coconut oil, Olive
oil and Castor oil was found to be 1.35 ± 0.05, 1.28 ± 0.04
and 2.11 ± 0.15 mg/ml respectively. The solubilities of glip-
izide in MCT such as Captex 300, Captex 355, Labrafac lipo-
phile WL1349, Labrafac PG and Miglyol 812 N were found to
be 5.12 ± 0.14, 5.55 ± 0.14, 4.45 ± 0.21, 4.08 ± 0.15 and
4.89 ± 0.22 mg/ml respectively. Solubility of glipizide was
found to be much higher in MCT than LCT. This may be
due to the shorter chain length and better ﬂuidity of MCT over
LCT (Bandyopadhyay et al., 2012). In addition, MCT are easy
to nanoemulsify as compared to LCT (Date et al., 2010). Thus,
Captex 355 was selected as the oily phase owing to its higher
solubilization capacity.
3.2. Screening of surfactant for emulsifying ability
The surfactant forms a thin ﬁlm at the interface, decreases the
globule size, helps in stabilization of the emulsion and exerts
their absorption enhancing effect by partitioning into the cell
membrane to disrupt the structural organization of the lipid
bilayer leading to permeation enhancement (Gursoy and
Benita, 2004). Only hydrophilic surfactants (HLB > 12) were
screened, as this will favor the formation of oil-in-water emul-
sion (Mohsin et al., 2009; Pouton, 2000). Only non-ionic sur-
factants were employed during this study because of less
toxicity as compared to the ionic one (Bali et al., 2011). The
results for surfactant screening were presented in supplemen-
tary table (Table S1). Out of all the surfactants screened, only
Cremophor RH40, Solutol HS15 and Labrasol were found to
possess good emulsifying abilities. Out of these, Solutol HS15
and Labrasol formed a spontaneous dispersion as compared
to Cremophor RH40, where the dispersion passed through
a noticeable intermediate crystalline phase. Among Solutol
HS15 and Labrasol, the dispersion obtained in case of
Solutol HS15 was associated with a lower turbidity (102.5
NTU) and higher transmittance (94.1%) as compared to
labrasol (296.6 NTU, and 82.5% transmittance). In case of
rest surfactants such as Cremophor EL and Tween 80, the
resulting dispersion formed a crystalline gel that was difﬁcult
to disperse. Solutol HS15 was selected for further study, due
to its good dispersibility ability. Solutol HS15 with an
average HLB of 15 has an inhibitory effect on p-gp enzymes,
thus increases intestinal absorption of drugs (Cornaire et al.,
2004). Solutol HS15 was reported to improve bioavailability
of some drugs formulated as self-emulsifying formulations,
such as Progesterone (Abdalla et al., 2008), Cefpodoxime
proxetil (Date and Nagarsenker, 2007), Dipyridamole (Guo
et al., 2011).
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The co-surfactant penetrates into the interface causing void
spaces for water penetration. This increases interfacial ﬂuidity
that facilitates spontaneous formation of emulsion (Nazzal
and Khan, 2002). The results for co-surfactant screening were
shown in supplementary table (Table S2). Imwitor 988 showed
the highest emulsifying ability as the dispersion obtained from
Imwitor 988 was found to be associated with a higher transmit-
tance (97.5%) along with lower turbidity (74.3 NTU) as com-
pared to the rest co-surfactant such as Capmul MCM (97.1%,
78.6 NTU), Capmul PG 8 (93.6%, 151.1 NTU), and PEG 400
(92.5%, 174.5 NTU). The results clearly indicated that lipophi-
lic co-surfactant like Imwitor 988, and Capmul MCM possess-
es better emulsifying ability than hydrophilic co-surfactant
such as PEG 400 and Capmul PG8, which contains hydrophi-
lic glycol moieties. Lipophilic co-surfactant, possesses a better
miscibility ability with MCT, has better ability to promote
emulsiﬁcation, has good solvent capacity for drugs and lack
of susceptibility to oxidation and hydrolysis compared to
hydrophilic co-surfactant (Pouton and Porter, 2008). Imwitor
988, having a short Caprylic acid (C8) back bone was selected
for the study due to a better emulsifying ability than Capmul
MCM (a mixture of C8 and C10 fatty acids). Co-surfactant
with a shorter molecular chain length is considered to be more
efﬁcient and has better ability to promote water penetration
(Date and Nagarsenker, 2007).
3.4. Ternary phase diagram
Ternary phase diagram was constructed in an absence of the
drug to identify the self-nanoemulsifying regions. Ternary
phase diagram was plotted for the selected oil (Captex 355),Figure 1 Contour plots (a and b) for mean droplet size (nm); (c and d
percentage (w/w) of Captex 355; X2, percentage (w/w) of Solutol HS1
represents actual data points.surfactant (Solutol HS15) and co-surfactant (Imwitor 988)
being each of them at the apex of a triangle (Gupta et al.,
2011) is shown in supplementary ﬁgure (Fig. S1). It was
observed that either a high or low concentration of oil, surfac-
tant and co-surfactant resulted in a turbid emulsion. The
region of a clear or slightly bluish dispersion (nanoemulsion
region) was appeared between the combination of Captex
355 (20–60% w/w), Solutol HS15 (20–60% w/w) and Imwitor
988 (10–30% w/w).
3.5. Optimization of SNEDDS preconcentrate using
experimental design
Following ternary phase diagram studies, a circumscribed
CCD (a= 1.682) was employed for the systematic optimiza-
tion of the SNEDDS. The self-emulsifying formulations of Sir-
olimus (Hu et al., 2012) and Baicalein (Liu et al., 2012) have
been optimized by circumscribed CCD. The ranges for oil, sur-
factant and co-surfactant for CCD based on the ranges as
obtained in phase diagram studies. In the present study, to test
self-nanoemulsiﬁcation efﬁciency of SNEDDS, water (HPLC)
used as dispersion media because a non-signiﬁcant difference
in droplet size has been observed if SNEDDS dispersed in
either water or GI ﬂuids (Shakeel et al., 2013).
3.5.1. Inﬂuence of factors on droplet size (nm)
The droplet size of the emulsion is a crucial factor in self-emul-
siﬁcation performance because it determines the rate and
extent of drug release as well as absorption (Pouton, 2006).
As it can be seen from Fig. 1a and b, an increase in % w/w
of Captex 355 tends to increase the droplet size where as a
reversed pattern was observed with Solutol HS15. The droplet
size was decreased with an increasing % w/w of Imwitor 988) for NTU and (e and f) for percentage transmittance. Where; X1,
5 and X3, percentage (w/w) of Imwitor 988. The small blue circle
Figure 2 Pareto charts for mean droplet size (nm) (a), NTU (b) and percentage transmittance (c). Where; X1, percentage (w/w) of
Captex 355; X2, percentage (w/w) of Solutol HS15 and X3, percentage (w/w) of Imwitor 988.
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(Y1) is as below Eq. (2).
Y1¼ 80:0416þ4:6121ðX1Þ4:167ðX2Þ2:388ðX3Þ
þ0:0201ðX1Þ2þ0:0448ðX2Þ2þ0:1087ðX3Þ2
0:0518ðX1 X2Þ0:1293ðX1 X3Þþ0:0463ðX2 X3Þ ð2Þ
The mean droplet size of diluted SNEDDS preconcentrates
were found to be between 20.9 nm and 238.4 nm (Table 1).
Pareto analysis of droplet size (Fig. 2a) shows the signiﬁcant
linear (X1) effect of Captex 355 (p< 0.05; Table 2), where
the coefﬁcient was found to be positive (Eq. (2)). This implies
that, an increase in Captex 355 leads to an increase in droplet
size. Whereas, the quadratic effect of Captex 355 (X1)2 was
found to be non-signiﬁcant (p> 0.05), indicating an absence
of any abrupt increase in droplet size with a gradual increase
in Captex 355 concentrations. An increase in Captex 355, a
hydrophobic MCT increases surface tension at the oil water
interface that proceeds through a liquid crystalline phase lead-
ing to coarser and aggregated droplet (Pouton and Porter,
2008). The linear (X2) effect of Solutol HS15 was found to
be signiﬁcant (p< 0.05; Table 2) with a negative coefﬁcient
(Eq. (2)), indicating a decrease in droplet size. This may be
attributed to the surface tension lowering property of surfac-
tant at the oil water interface that lessens the free energy
required for the formation of ﬁner emulsion (Gursoy and
Benita, 2004). A signiﬁcant (p< 0.05, Table 2) negative inter-
action (decrease in droplet size) was observed between Captex
355 and Solutol HS15 (X1X2), signifying Solutol HS15 suc-
cessfully counteracted the increase in interfacial surface ten-
sion caused by Captex 355. This in turn decreased the
droplet size. In contrast, the quadratic effect of Solutol HS15
(X2)2 was found to be signiﬁcant (p< 0.05; Table 2) having
a positive coefﬁcient (an increase in droplet size) (Coefﬁcient:
+0.0448, Eq. (2)). This might be due to an enhanced water
penetration into the oil droplets mediated by excess surfactantconcentration causing disruption of interfacial surface and led
to the ejection of oil droplets into the aqueous phase, which in
turn forms a coarse emulsion having larger droplet size
(Gursoy and Benita, 2004). The linear effect of Imwitor 988
(X3) was found to be non-signiﬁcant (p> 0.05; Table 2) indi-
cating co-surfactant by itself does not possess emulsifying abil-
ity; rather it acts by enhancing water penetration and
interfacial ﬂuidity (Pouton and Porter, 2008). This phe-
nomenon was veriﬁed by a signiﬁcant (p< 0.05; Table 2)
negative interaction that observed between Captex 355 and
Imwitor 988 (X1X3), which indicate the ability of Imwitor
988 to counteract the effect of Captex 355 and providing more
ﬂexibility for the rupture of liquid crystalline phase to enhance
water penetration. And this interactive effect (X1X3) had the
most profound effect upon droplet size owing to its highest
F value (22.80, Table 2) and the longest bar length as shown
in Pareto chart (Fig. 2a). A signiﬁcant (p< 0.05; Table 2)
interaction bearing positive coefﬁcient (+0.0463, Eq. (2)) (an
increase in droplet size) was observed between Solutol HS15
and Imwitor 988 (X2X3). This may be due to an additive water
penetrating effect of surfactant and co-surfactant causing dis-
ruption of interfacial surface leading to ejection of oil droplets
into the aqueous phase. The average difference between pre-
dicted and experimental mean droplet size was approximately
8.0 nm and the largest difference was 18.4 nm.3.5.2. Inﬂuence of factors on turbidity (NTU)
Turbidity can be used as an indirect measure of emulsion dro-
plet size as a direct correlation been observed between the
intensity of scattered light and the volume of dispersed dro-
plets (Nazzal and Khan, 2002). From the contour plot
(Fig. 1c), it was found that the turbidity was decreased
gradually with an increase (up to 50% w/w) in Captex 355.
Turbidity was increased with a further increase in % w/w of
Captex 355. Turbidity was found to be decreased with an
Table 2 Analysis of variance (ANOVA) of models.
Source DF a Y1 Y2 Y3
Fb pc Fb pc Fb pc
Regression 9 22.68 <0.001* 41.82 <0.001* 33.36 <0.001*
Linear 3 14.43 0.001* 10.87 0.002* 12.24 0.001*
X1 1 16.60 0.002* 9.63 0.011* 11.62 0.007*
X2 1 13.55 0.004* 13.69 0.004* 14.26 0.004*
X3 1 1.11 0.316 0.48 0.504 0.86 0.374
Square 3 8.90 0.004* 22.36 <0.001* 15.03 <0.001*
X1*X1 1 3.97 0.074 23.66 0.001* 19.53 0.001*
X2*X2 1 19.72 0.001* 31.44 <0.001* 29.51 <0.001*
X3*X3 1 7.25 0.023* 25.21 0.001* 2.24 0.166
Interaction 3 13.46 0.001* 17.22 <0.001* 20.15 <0.001*
X1*X2 1 14.66 0.003* 12.25 0.006* 40.04 <0.001*
X1*X3 1 22.80 0.001* 37.38 <0.001* 15.12 0.003*
X2*X3 1 2.92 0.118 2.03 0.185 5.30 0.044*
Lack-of-ﬁt 5 1.25 0.293 0.69 0.425 0.82 0.382
X1, Captex 355; X2, Solutol HS 15 and X3, Imwitor 988; Y1, mean droplet size (nm); Y2, turbidity (NTU); Y3, percentage transmittance.
a DF, degree of freedom.
b F, test for comparing model variance with residual variance.
c p, probability of seeing the observed F-value if the null hypothesis is true.
* Signiﬁcant model terms (p< 0.05).
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The regression equation for turbidity (Y2) is as below in Eq.
(3).
Y2¼ 77:4078þ4:0379ðX1Þ4:8147ðX2Þ1:8048ðX3Þ
þ0:0564ðX1Þ2þ0:065ðX2Þ2þ0:233ðX3Þ2
0:0545ðX1 X2Þ0:1904ðX1 X3Þ0:0444ðX2 X3Þ ð3Þ
The observed turbidities of the diluted SNEDDS precon-
centrates were found to be within 4.6–275.8 NTU (Table 1).
It can be concluded from Pareto chart (Fig. 2b) and ANOVA
(Table 2), that all the model terms, except X3 and X2X3 were
found to be signiﬁcant (p< 0.05; Table 2). A signiﬁcant
(p< 0.05; Table 2) negative interaction (a decrease in tur-
bidity) was observed between Captex 355 and Solutol HS15
as well as between Captex 355 and Imwitor 988. The later
was found to be the most signiﬁcant one affecting turbidity
due to its highest F value (37.38, Table 2). The average and lar-
gest difference between observed and predicted turbidity was
found to be 10.5 NTU and 24.4 NTU respectively. The results
indicated that, the signiﬁcance as well as the direction of these
effects upon turbidity (Y2) was similar to the effects as
observed upon droplet size (Y1) except the quadratic effect
of Captex 355 (X1)2. (X1)2 had a signiﬁcant (p< 0.05) effect
upon turbidity whereas its effect upon the droplet size was
non-signiﬁcant (p> 0.05). A good correlation (r2 = 0.919)
was observed between turbidity and droplet size.
3.5.3. Inﬂuence of factors on percentage transmittance
A value of percentage transmittance closer to 100% indicates
that the dispersion of SNEDDS was clear and transparent with
a droplet size that approximates the nanometer range. This in
turn provides a large surface area for the drug release and
absorption in the GI tract (Bali et al., 2011). From Fig. 1e, it
can be observed that, initially percentage transmittance
increased by an increase in Captex 355 (up to 50% w/w). How-
ever, percentage transmittance was decreased with a furtherincrease in % w/w of Captex 355. Percentage transmittance
was increased by an increasing % w/w of Solutol HS15 and
Imwitor 988 (Fig. 1e and f). The regression equation obtained
for percentage transmittance is as follows Eq. (4).
Y3¼ 91:47130:584ðX1Þþ0:6471ðX2Þþ0:3187ðX3Þ
0:0067ðX1Þ20:0083ðX2Þ20:0091ðX3Þ2
þ0:013ðX1 X2Þþ0:0159ðX1 X3Þ0:0094ðX2 X3Þ ð4Þ
The range of percentage obtained after diluting SNEDDS
preconcentrates varied between 64.8% and 99.9% (Table 1).
It can be seen from the Pareto chart (Fig. 2c), that all the mod-
el terms except linear (X3) and quadratic (X3)2 effects of Imwi-
tor 988 were found to be signiﬁcant (p< 0.05; Table 2).
Signiﬁcant (p< 0.05; Table 2) positive interaction was
observed between Captex 355 and Solutol HS15 (X1X2) as well
as between Captex 355 and Imwitor 988 (X1X3). A signiﬁcant
(p< 0.05; Table 2) negative interaction (a decrease in percent-
age transmittance, unfavorable) was observed between Solutol
HS15 and Imwitor 988 (X2X3). Out of all the model terms,
X1X2 had the most profound effect upon percentage transmit-
tance owing to its highest bar length as observed in Pareto
chart (Fig. 2c) and highest F value (40.04, Table 2). The aver-
age difference between observed and predicted transmittance
was 1.24% and the largest difference was 3.5%. From these
results, it can be clearly observed that the effects of factors
upon percentage transmittance (Y3) were very similar to the
effects as observed upon the droplet size but in an opposite
direction. A good correlation (r2 = 0.946) between percentage
transmittance and droplet size was observed. Thus, this study
supports the previous works, those employ percentage trans-
mittance as one of the quality parameters for characterization
of SNEDDS (Bali et al., 2010, 2011; Rahman et al., 2012).
Hence, the measurement of percentage transmittance and tur-
bidity of diluted SNEDDS by simpler equipment could be
alternative techniques rather than measuring droplet size by
expensive and sophisticated equipment.
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The ANOVA Result (Table 2) depicts a high F value (22.68 for
Y1, 41.82 for Y2 and 33.36 for Y3) along with a low ‘‘p’’ value
(p< 0.001). In addition, it can be observed from Table 2, that
the lack of ﬁts were found to be non-signiﬁcant (p> 0.05) for
each model, indicating that the proposed models are appropri-
ate and signiﬁcant. The relationships between observed and
predicted responses was found to be linear and acceptable as
the adjusted R2 values were higher than 0.8 (0.9112 for Y1,
0.9508 for Y2 and 9387 for Y3) as suggested by Lundstedt
et al., 1998 for chemical samples. Residuals for all responses
were found to be homogenous, structure less and having an
independence pattern that distributed equally above and below
0-line. The residuals were normally distributed and resembled
a straight line for each response. This implies that the pro-
posed models are adequate, and the variance of the experimen-
tal measurements is constant at all values of responses
(Montgomery, 2013).
3.5.5. Derringer’s desirability and optimization of SNEDDS
The aim of this optimization was set to determine the levels of
the factors from which SNEDDS with high-quality character-
istics may be produced. As per the method goal, some of the
responses desired to be minimized such as droplet size
(<50 nm) and turbidity (<20 NTU), whereas at the same time
some response such as percentage transmittance desired to be
maximized (>99%). Under these conditions, the desirability
(d) of each of the responses can be combined to get global
desirability (dG) that can be employed to get an optimum com-
bination of factors (Derringer and Suich, 1980). dG can be rep-
resented as Eq. (5).
dG ¼ ½d1p1xd2p2x . . . x  dnpn1=n ð5Þ
where the dimensionless term ‘‘d’’ (Derringer’s desirability
function) varies between 0 (undesirable) and 1 (fully desirable),
d1 . . . dn is the individual desirability for 1 . . . n number of
responses; p is the weight of the responses. A value of dG (1
or closer to 1) is required for getting perfect target values for
factors. The goal used for droplet size (nm) and turbidity
(NTU) minimized and maximized for percentage transmit-
tance. The weight of the responses (p) was set equal to 1.
The global desirability was found to be 0.99, which is very
close to 1 for the optimal SNEDDS consisted of Captex 355
(30% w/w), Solutol HS15 (45% w/w) and Imwitor 988
(25% w/w).
3.6. Solubility of glipizide in optimized SNEDDS and loading
of glipizide
Conventionally, the drug loading in SNEDDS is based on the
solubility in oil phase rather than the drug solubility in
SNEDDS preconcentrate (a mixture of oil, surfactant and
co-surfactant). However, to improve the drug loading capacity
of SNEDDS, some studies loaded the drug in between 75%
and 200% SS in SNEDDS preconcentrate (Pund et al., 2014;
Shakeel et al., 2013; Thomas et al., 2013, 2012). Saturation
solubility of glipizide in optimized SNEDDS preconcentrate
and water was found to be 45.12 ± 1.36 mg/ml, and
0.033 ± 0.0021 mg/ml respectively. The result indicates a sig-
niﬁcant (p< 0.001) enhancement in glipizide solubility
(1367-fold) occurred in optimized SNEDDS preconcentrateas compared to its aqueous solubility. However, in order to
solubilize glipizide within a short mix-up time, it was loaded
at 90% SS level (40 mg/ml) in the optimized SNEDDS
preconcentrate.
3.7. Characterization of liquid SNEDDS
3.7.1. Thermodynamic stability studies
Nanoemulsion is the thermodynamically stable systems with-
out phase separation, creaming and cracking, which differenti-
ate it from the micro-emulsion. Thermodynamic stability
studies have a vital importance in developing self-emulsifying
formulation as a phase separation can be observed in case of
unstable formulation (Rahman et al., 2012). Hence, the
SNEDDS examined for centrifugation, and heating–cooling
cycle, passed these tests as no phase separation, creaming
and cracking were observed.
3.7.2. Cloud point measurement
Estimation of cloud point is an important factor for the sta-
bility of self-emulsifying formulation. The cloud point is the
temperature above which dehydration of self-emulsifying
ingredients occurs and turns a clear dispersion to a cloudy
one which in turn may affect drug absorption (Gupta et al.,
2011). Hence, cloud point of self-emulsifying formulation
should be above body temperature (37 C). The cloud point
of SNEDDS was found to be 74 C, indicating the formed
nanoemulsion at the physiological temperature will be a stable
one.
3.7.3. Droplet size analysis and zeta potential analysis
Fig. 3a depicts the mean droplet size along with a size distribu-
tion of liquid SNEDDS. The mean droplet size was found to
be 29.4 nm. The zeta potential of the liquid SNEDDS was
found to be 35.0 mV. The negative value of zeta potential
may be due to the presence of free fatty acids. A Negative val-
ue to the zeta potential of the optimized formulations indicated
that the formulations were negatively charged, and sufﬁcient
repulsion among emulsion droplets existed to form an un-co-
agulated system and therefore, gives an indication of a stable
system (Parmar et al., 2011).
3.7.4. Measurement of transmittance and turbidity
The turbidity and transmittance of the diluted liquid SNEDDS
were found to 6.7 ± 0.1 NTU and 99.7 ± 0.01% respectively
(n= 3).
3.7.5. Transmission electron microscopy
TEM image of diluted SNEDDS is shown in Fig. 3b. The
nanoemulsion droplets were appeared to be un-coagulated
and spherical with a dark background. The droplet size was
found to be below 100 nm, having size distribution similar to
the result as obtained by DLS technique.
3.8. Characterization of solid SNEDDS
3.8.1. Droplet size of reconstitute solid SNEDDS
The mean droplet size of reconstituted solid SNEDDS was
found to be 29.8 and was non-signiﬁcant (p> 0.05) when
compared to the droplet size as observed in case of liquid
Figure 3 (a) Dynamic light scattering data of the diluted liquid SNEDDS (500 times with HPLC water); (b) transmission electron
microscope image of the diluted liquid SNEDDS (500 times with HPLC water), bar length represents 100 nm.
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tion property of liquid SNEDDS.
3.8.2. Micromeritic properties
Solid SNEDDS showed a good ﬂow property with Carr’s
index between 18 and 20, Hausner’s ratio within 1.22–1.25
and angle of repose between 25 and 30.
3.8.3. Scanning electron microscopy (SEM)
The scanning electron micrographs of glipizide, solid
SNEDDS, solid SNEDDS blank and physical mixtures were
shown in Fig. 4. Glipizide (Fig. 4a) appeared as smooth sur-
faced rectangular crystals, which can be seen in the physical
mixture (Fig. 4d). Whereas glipizide crystals were absent in
solid SNEDDS (Fig. 4b), the surface of which was found to
be in close resemblance with the agglomerated and rough sur-
faced solid SNEDDS blank (Fig. 4c). This suggests that the
glipizide was absorbed and molecularly dissolved inside theFigure 4 Scanning electron micrograph of: (a) glipizide; (b) solid SN
and solid SNEDDS blank.pores of the excipient’s matrix of solid SNEDDS. The micro-
porous surface of the matrix might form channels for water
inﬁltration, which could facilitate dispersion and formation
of nanoemulsion as suggested by Hu et al., 2012.
3.8.4. Powder XRD studies
X-ray diffractogram of glipizide (Fig. 5a) exhibited several
sharp peaks at 7.4, 10.0, 11.0, 15.7, 16.9, 18.0, 18.7,
19.2, 20.5, 21.0, 21.8, 22.2, 23.6, 24.3, 24.7, 25.3,
26.8 and 28.7 respectively. This was found to be similar to
the one reported earlier by Huang et al., 2013. The high-inten-
sity peaks due to glipizide and each excipient were seen in the
physical mixture (Fig. 5b). Calcium carbonate showed sharp
peaks at 19.2, 19.7, 20.1 and 29.5 (Fig. 5e). Talc showed
sharp peaks at 9.5, 19.1, 19.5, 28.7 and 36.4 (Fig. 5f).
These peaks of calcium carbonate and talc were appeared in
solid SNEDDS blank (Fig. 5d), solid SNEDDS (Fig. 5c) and
physical mixture (Fig. 5b). In case of solid SNEDDSEDDS; (c) solid SNEDDS blank; (d) physical mixture of glipizide
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Figure 5 Powdered XRD diffractogram of: (a) glipizide; (b)
physical mixture of glipizide and solid SNEDDS blank; (c) solid
SNEDDS; (d) solid SNEDDS blank; (e) calcium carbonate and
(f) talc.
Figure 7 In-vitro release proﬁle of liquid SNEDDS, solid
SNEDDS, marketed product (Glucotrol) and pure drug.
538 R.N. Dash et al.(Fig. 5c), the major peaks of glipizide (at 7.4, 11.0, 15.7,
16.9 and 22.2) were found to be of reduced intensity along
with a complete absence at 18.0 and 18.7. This suggests that,
the crystalline property of glipizide has been reduced within
the solid SNEDDS, where it is present in an amorphous form.
3.8.5. Differential scanning calorimetry (DSC)
DSC thermograms of glipizide, physical mixture, solid
SNEDDS, solid SNEDDS blank and excipients were present-
ed in the Fig. 6. It can be observed that, glipizide exhibited a
sharp melting endothermic peak at 211.4 C corresponds to
its melting point that initiated from 207.9 C (Fig. 6a). Physi-
cal mixture showed an endothermic peak with reduced intensi-
ty relative to the pure glipizide (Fig. 6b). In case of physical
mixture, solubilization of glipizide crystals within solid
SNEDDS blank during heating might lead to an obtuse peak
with reduced intensity. Solid SNEDDS (Fig. 6c) did not show40 60 80 100 120 140 160 180 200 220 240 260 280 300 320
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Figure 6 Differential scanning calorimetry (DSC) thermograms
of: (a) glipizide; (b) physical mixture of glipizide and solid
SNEDDS blank; (c) solid SNEDDS; (d) solid SNEDDS blank;
(e) calcium carbonate and (f) talc.any endothermic peak of glipizide, and its thermogram resem-
bled like thermogram of solid SNEDDS blank (Fig. 6d).
Hence, it can be concluded that glipizide was dissolved into
the excipient matrix of solid SNEDDS. This has also indicated
a change in the physical nature of glipizide from crystalline
state to the amorphous one.
3.8.6. In-vitro dissolution studies
In the self-emulsifying systems, the free energy necessary to
form an emulsion is very low, thereby allowing the sponta-
neous formation of the oil/water interface. It is proposed that
the oil/surfactant/co-surfactant and water phases effectively
swell to decrease the droplet size, and eventually increase the
release rate (Balakrishnan et al., 2009). The percentage drug
release in 15 min (DR15min) for liquid-SNEDDS, solid-
SNEDDS, Glucotrol, and pure drug was found to be 99.65,
97.33, 65.82, and 18.37 respectively (Fig. 7). This increase in
DR15min in case of liquid SNEDDS and solid SNEDDS was
signiﬁcant as compared to Glucotrol and pure drug. Howev-
er, the difference observed between DR15min of solid SNEDDS
and liquid SNEDDS was found to be non-signiﬁcant
(p> 0.05), indicating that the solid SNEDDS preserved the
improvement of the in-vitro dissolution of liquid SNEDDS.
Initially, the glipizide release from solid SNEDDS was
marginally slower than its release from liquid SNEDDS,
though the difference was statistically non-signiﬁcant
(p> 0.05). This could be due to an increase in diffusion path
length for the liquid SNEDDS that adsorbed within the por-
ous matrix of solid SNEDDS (Dixit and Nagarsenker, 2008).
The superior drug release from solid SNEDDS might be
attributed to the presence of amorphous glipizide within as
conﬁrmed from PXRD and DSC results. Amorphous form
requires less energy to dissolve, resulting in higher apparent
solubilities and increased dissolution rates (Seo et al., 2013).
In addition, as evident from the SEM results, since glipizide
is molecularly dissolved within the solid SNEDDS matrix, a
high surface area might have generated to improve wettability
and in-vitro release of the drug. Furthermore, smaller droplet
size of the nanoemulsion generated for reconstituted solid
SNEDDS might have generated a larger surface area for rapid
drug release.
Glipizide solid self-nanoemulsifying drug delivery for enhanced solubility and dissolution 5394. Conclusion
In the present study, the formation of a nanoemulsion follow-
ing dilution of solid SNEDDS was possible because of careful
selection and optimization of excipients. The nanoemulsion
was found to possess predetermined quality attributes as speci-
ﬁed in the goal. PXRD and DSC studies indicated loss of crys-
tallinity of drug within the solid SNEDDS. This result was
veriﬁed by the scanning electron microscopy studies, which
revealed no evidence of drug precipitation on the surface of
the carrier. Solid SNEDDS found to be free ﬂowing in nature,
preserved the selfemulsifying property of liquid SNEDDS and
showed a signiﬁcant increase in dissolution of glipizide as com-
pared with pure drug and commercial tablet. However, further
pharmacokinetic/pharmacodynamic investigations on animal/
human models are needed to exploit the maximum potential
of solid SNEDDS for glipizide.
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